Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Hybio Pharmaceutical Co. Ltd (Site 1)
EIR
•Hybio Pharmaceutical Co. Ltd (Site 1)•March 30, 2018

Hybio Pharmaceutical Co. Ltd (Site 1) – FDA EIR, Mar 30, 2018

Record Details

An FDA inspection of Hybio Pharmaceutical Co. Ltd, located in Shenzhen, China, was conducted from March 26-30, 2018. This comprehensive inspection, part of an FDA drug surveillance program, focused on the company's manufacturing of non-sterile active pharmaceutical ingredients (APIs). The regulatory framework included Compliance Program 7356.002F for Bulk Pharmaceutical Chemicals and ICH Q7 Good Manufacturing Practice Guidance for APIs. The inspection identified several issues, leading to an FDA-483 observation document. Primary violations included the company's failure to verify that the specified 2-8°C storage conditions for starting material labels were maintained during transportation. Additionally, batch records were found to be incomplete, lacking details on transferred bucket usage and full label specimens. The labeling of shipped APIs also omitted necessary caution statements. While a previous inspection in 2015 had resulted in similar observations, the current inspection confirmed that corrections to those earlier issues had been made. For the recent findings, Hybio Pharmaceutical Co. Ltd management committed to addressing the observations and submitting a written response within 15 days. The inspection was categorized as "Voluntary Action Indicated" (VAI), signifying that while observations were made, the firm voluntarily agreed to take corrective actions without immediate regulatory enforcement.

Company
Hybio Pharmaceutical Co. Ltd (Site 1)
Inspection date
March 30, 2018
Product type
drugs
Office
Office of Pharmaceutical Quality Operations
People
  • Kevin A. Gonzalez (Branch Chief, Foreign Pharmaceutical Quality Inspection at FDA)
  • Kham Phommachanh (Investigator)
View Company Profile

ID · 372a5947-486f-439d-8e42-5e8561b837ef

Violation Codes1
21 CFR 211

Full citation text and observation details available on the Dashboard.

Other documents for Hybio Pharmaceutical Co. Ltd (Site 1)
  • 483 - 2015-06-26June 26, 2015
  • EIR - 2015-06-26June 26, 2015

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Hybio Pharmaceutical Co. Ltd (Site 1)
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.